Phase 2WithdrawnINTERVENTIONAL
90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)
ClinicalTrials.gov · NCT01048086 · Registry updated: 2016-06-21
- Condition / research focus
- Neuroblastoma; Neuroendocrine Tumor
- Sponsor
- University of Iowa
- Countries with listed sites
- United States
- Registry dates and results
- Start: 2009-06. Completion: 2013-11 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Retinoic Acid (drug) — also listed as: 13-cis retinoic acid
- Placebo (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
Site recruitment: Not reported